116 related articles for article (PubMed ID: 38727834)
1. MASCC 2023 Patient-Centered Antiemetic Guidelines and Education Statements: an evidence-based and consensus resource for patients.
Affronti ML; Lee J; Molassiotis A; Johnson L; Tinianov S; Clark-Snow R; Scotte F
Support Care Cancer; 2024 May; 32(6):335. PubMed ID: 38727834
[TBL] [Abstract][Full Text] [Related]
2. Radiation-induced nausea and vomiting: a comparison between MASCC/ESMO, ASCO, and NCCN antiemetic guidelines.
McKenzie E; Zaki P; Raman S; Olson R; McFarlane T; DeAngelis C; Chan S; Pidduck W; Razvi Y; Bushehri A; Chow E
Support Care Cancer; 2019 Mar; 27(3):783-791. PubMed ID: 30607675
[TBL] [Abstract][Full Text] [Related]
3. 2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
Olver I; Ruhlmann CH; Jahn F; Schwartzberg L; Rapoport B; Rittenberg CN; Clark-Snow R
Support Care Cancer; 2017 Jan; 25(1):297-301. PubMed ID: 27572335
[TBL] [Abstract][Full Text] [Related]
4. Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data.
Aapro M; Scotté F; Escobar Y; Celio L; Berman R; Franceschetti A; Bell D; Jordan K
Oncologist; 2021 Jun; 26(6):e1073-e1082. PubMed ID: 33555084
[TBL] [Abstract][Full Text] [Related]
5. 2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting.
Ruhlmann CH; Jahn F; Jordan K; Dennis K; Maranzano E; Molassiotis A; Roila F; Feyer P
Support Care Cancer; 2017 Jan; 25(1):309-316. PubMed ID: 27624464
[TBL] [Abstract][Full Text] [Related]
6. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice.
Jordan K; Gralla R; Jahn F; Molassiotis A
Eur J Pharmacol; 2014 Jan; 722():197-202. PubMed ID: 24157984
[TBL] [Abstract][Full Text] [Related]
7. Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs.
Pastore D; Bruno B; Carluccio P; De Candia MS; Mammoliti S; Borghero C; Chierichini A; Pavan F; Casini M; Pini M; Nassi L; Greco R; Tambaro FP; Stefanoni P; Console G; Marchesi F; Facchini L; Mussetti A; Cimminiello M; Saglio F; Vincenti D; Falcioni S; Chiusolo P; Olivieri J; Natale A; Faraci M; Cesaro S; Marotta S; Proia A; Donnini I; Caravelli D; Zuffa E; Iori AP; Soncini E; Bozzoli V; Pisapia G; Scalone R; Villani O; Prete A; Ferrari A; Menconi M; Mancini G; Gigli F; Gargiulo G; Bruno B; Patriarca F; Bonifazi F
Ann Hematol; 2020 Apr; 99(4):867-875. PubMed ID: 32036421
[TBL] [Abstract][Full Text] [Related]
8. 2023 Updated MASCC/ESMO Consensus Recommendations: prevention of radiotherapy- and chemoradiotherapy-induced nausea and vomiting.
Ruhlmann CH; Jordan K; Jahn F; Maranzano E; Molassiotis A; Dennis K
Support Care Cancer; 2023 Dec; 32(1):26. PubMed ID: 38097904
[TBL] [Abstract][Full Text] [Related]
9. Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential.
Olver I; Clark-Snow RA; Ballatori E; Espersen BT; Bria E; Jordan K
Support Care Cancer; 2011 Mar; 19 Suppl 1():S33-6. PubMed ID: 20803222
[TBL] [Abstract][Full Text] [Related]
10. 2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents.
Scotté F; Schwartzberg L; Iihara H; Aapro M; Gralla R; Hesketh PJ; Jordan K; Chow R; Herrstedt J
Support Care Cancer; 2023 Dec; 32(1):45. PubMed ID: 38114821
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art.
Grunberg SM; Warr D; Gralla RJ; Rapoport BL; Hesketh PJ; Jordan K; Espersen BT
Support Care Cancer; 2011 Mar; 19 Suppl 1():S43-7. PubMed ID: 20972805
[TBL] [Abstract][Full Text] [Related]
12. 2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
Olver I; Clark-Snow R; Ruhlmann CH; Garcia-Del-Barrio MA; Schwartzberg L; Rapoport BL; Jahn F
Support Care Cancer; 2023 Dec; 32(1):37. PubMed ID: 38110581
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009.
Feyer PC; Maranzano E; Molassiotis A; Roila F; Clark-Snow RA; Jordan K;
Support Care Cancer; 2011 Mar; 19 Suppl 1():S5-14. PubMed ID: 20697746
[TBL] [Abstract][Full Text] [Related]
14. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
Einhorn LH; Rapoport B; Navari RM; Herrstedt J; Brames MJ
Support Care Cancer; 2017 Jan; 25(1):303-308. PubMed ID: 27815710
[TBL] [Abstract][Full Text] [Related]
15. Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
Koch S; Wein A; Siebler J; Boxberger F; Neurath MF; Harich HD; Hohenberger W; Dörje F
Support Care Cancer; 2013 Sep; 21(9):2395-402. PubMed ID: 23568765
[TBL] [Abstract][Full Text] [Related]
16. Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation.
Jordan K; Chan A; Gralla RJ; Jahn F; Rapoport B; Ruhlmann CH; Sayegh P; Hesketh PJ
Support Care Cancer; 2023 Dec; 32(1):53. PubMed ID: 38129530
[TBL] [Abstract][Full Text] [Related]
17. Use of antiemetics in the management of chemotherapy-related nausea and vomiting in current UK practice.
Molassiotis A; Brearley SG; Stamataki Z
Support Care Cancer; 2011 Jul; 19(7):949-56. PubMed ID: 20574666
[TBL] [Abstract][Full Text] [Related]
18. 2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy.
Herrstedt J; Roila F; Warr D; Celio L; Navari RM; Hesketh PJ; Chan A; Aapro MS
Support Care Cancer; 2017 Jan; 25(1):277-288. PubMed ID: 27443154
[TBL] [Abstract][Full Text] [Related]
19. Antiemetics: an update and the MASCC guidelines applied in clinical practice.
Herrstedt J
Nat Clin Pract Oncol; 2008 Jan; 5(1):32-43. PubMed ID: 18097455
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy.
Chan A; Low XH; Yap KY
J Manag Care Pharm; 2012 Jun; 18(5):385-94. PubMed ID: 22663171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
